NYMC Faculty Publications
Use of Tafenoquine to Treat a Patient With Relapsing Babesiosis With Clinical and Molecular Evidence of Resistance to Azithromycin and Atovaquone
Author Type(s)
Faculty
DOI
10.1016/j.idcr.2022.e01460
Journal Title
Idcases
First Page
e01460
Document Type
Article
Publication Date
1-1-2022
Department
Medicine
Abstract
Tafenoquine is a highly effective treatment for infections in animal models. An immunocompromised patient infected by a strain of that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.
Recommended Citation
Marcos, L. A., Leung, A., Kirkman, L., & Wormser, G. P. (2022). Use of Tafenoquine to Treat a Patient With Relapsing Babesiosis With Clinical and Molecular Evidence of Resistance to Azithromycin and Atovaquone. Idcases, 27, e01460. https://doi.org/10.1016/j.idcr.2022.e01460